Résumé
In the early days of the pandemic, clinical biomarkers for COVID -19 have been investigated to predict patient mortality. A decision tree has been proposed previously comprising three variables, i.e., lactic dehydrogenase (LDH), high-sensitivity C-reactive protein (CRP), and lymphocyte percentage, with more than 90% accuracy in a public cohort. In this work, we highlighted the importance of the cohort made publicly available and complemented the findings by incorporating further evaluation. Results confirmed poor short-term prognosis to abnormal levels of some laboratorial indicators, such as LDH, CRP, lymphocytes, interleukin-6, and procalcitonin. In addition, our findings provide insights into COVID-19 research, such as key levels of fibrin degradation products, which are directly associated with the Dimerized plasmin fragment D and could indicate active coagulation and thrombosis. Still, we highlight here the prognostic value of interleukin-6, a cytokine that induces inflammatory response and may serve as a predictive biomarker.